Clinical course and long-term outcomes in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy
Open Access
- 26 May 2025
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (6) , 1-12
Abstract
Background: The aim was to describe the clinical course and long-term outcomes of the French cohort of patients with glial fibrillary acidic protein (GFAP) astrocytopathy. Methods: Patients with positive CSF GFAP antibody test were identified between May 2017 and February 2023. Those whose clinical presentation occurred < 2 years before the initiation of the study, with other diagnosis than GFAP astrocytopathy, and with missing clinical information were excluded. Results: Among the 74 patients included, 71 were alive at last follow-up. The median age at onset was 43 years (range 6–84), 44 patients were male (62%), and 11 (15%) had a neoplasia. The main initial syndrome was meningo-encephalitis (n = 41, 58%). The median follow-up was 28 months (range 1–129). The median mRS at presentation was 4 (range 1–5) and at last follow-up was 1 (range 0–4). Forty patients reported disability at last follow-up (56%). The most frequent sequelae were cognitive complaints (20/40, 50%) and gait disorder (19/40, 48%). 38/55 patients (69%) returned to school/work. Long-term immunoactive treatment was introduced in 40 patients (56%); the most commonly administered were oral corticosteroids (n = 35, 49%). Relapses were documented in 10 patients (14%) and occurred after a median follow-up of 9 months (range 3–46). The presence of concomitant tumor at onset was associated with relapse (HR 4.55, 95% CI 1.28–16.14, p = 0.03). Conclusions: This study suggests a greater impact than previously described in long-term outcomes of patients with GFAP astrocytopathy and reports concomitant tumor at presentation as a risk factor for relapse.Keywords
Funding Information
- Agence Nationale de la Recherche (ANR-18-RHUS-0012)
- Hospices Civils de Lyon
This publication has 21 references indexed in Scilit:
- Glial Fibrillary Acidic Protein AutoimmunityNeurology, 2022
- Clinical, neuroradiological, diagnostic and prognostic profile of autoimmune glial fibrillary acidic protein astrocytopathy: A pooled analysis of 324 cases from published data and a single-center retrospective studyJournal of Neuroimmunology, 2021
- Clinical characteristics of autoimmune GFAP astrocytopathyJournal of Neuroimmunology, 2019
- Autoimmune glial fibrillary acidic protein astrocytopathyCurrent Opinion in Neurology, 2019
- Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Review of the LiteratureFrontiers in Immunology, 2018
- Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1 yearJournal of Neuroimmunology, 2018
- Autoimmune glial fibrillary acidic protein astrocytopathy in Chinese patients: a retrospective studyEuropean Journal of Neurology, 2017
- Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patientsJournal of Neurology, Neurosurgery & Psychiatry, 2017
- Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patientsAnnals of Neurology, 2017
- Autoimmune Glial Fibrillary Acidic Protein AstrocytopathyJAMA Neurology, 2016